We identify, evaluate, negotiate and in-license oncology assets with strong value creation opportunities. Asset classes of interest include:

• DNA repair modulators
• Cancer metabolism modulators
• Chromatin and histone modulators
• Well-defined pathway node inhibitors with commercial and clinical proof of concept

We may consider alternative asset classes with strong data packages, clear differentiators and value inflection points, which can then be incorporated into future development strategies.

Clinical Development Strategies
With significant experience in translational oncology drug development, coupled with proven success in clinical trial design and implementation, Cumulus Oncology designs early phase trials to add value to oncology assets. Innovative study design and conduct, biomarker lead development, access to a world class network of oncology KOLs, investigator sites and oncology drug development experts facilitates this approach.